Holly E. Barker
Impact in
- Oncology top 2%
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Cell Adhesion Molecules Research 3
- Oncology 13
- Cancer-related Molecular Pathways 4
- Cancer Cells and Metastasis 3
- Co-authors
- Kevin J. HarringtonJames PagetAadil KhanJanine T. ErlerThomas R. CoxGeorgina LangD. K. BirdAnn‐Marie Baker
- Journals
- Nature reviews. Cancer (4 papers)Cancer Research (4 papers)Molecular Cancer Therapeutics (2 papers)Radiotherapy and Oncology (2 papers)iScience (1 paper)
- Partner nations
- United KingdomAustraliaUnited States
In The Last Decade
Holly E. Barker
27 papers receiving 3.8k citations
Hit Papers
Peers
Comparison fields: 5 of 109
- Oncology 1.7k
- Cancer Research 839
- Immunology 638
- Molecular Biology 1.8k
- Immunology and Allergy 158
Countries citing papers authored by Holly E. Barker
This map shows the geographic impact of Holly E. Barker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holly E. Barker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holly E. Barker more than expected).
Fields of papers citing papers by Holly E. Barker
This network shows the impact of papers produced by Holly E. Barker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holly E. Barker. The network helps show where Holly E. Barker may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Holly E. Barker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 4 | |
| 3 | 2023 | 1 | |
| 4 | Chaperone-mediated protein degradation (CHAMP): A novel technology for tumor-targeted protein degradation. | 2021 | 2 |
| 5 | 2019 | 9 | |
| 6 | 2019 | 6 | |
| 7 | SRA737, a novel Chk1 inhibitor, shows efficacy in CCNE1-amplified and MYCN-overexpressing high-grade serous ovarian cancer patient-derived xenograft models | 2018 | 1 |
| 8 | 2018 | 41 | |
| 9 | 2017 | 20 | |
| 10 | 2017 | 29 | |
| 11 | 2016 | 40 | |
| 12 | 2016 | 82 | |
| 13 | 2015 | 26 | |
| 14 | The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence Hit paper breakdown → | 2015 | 1605 |
| 15 | 2013 | 80 | |
| 16 | 2013 | 31 | |
| 17 | 2012 | 461 | |
| 18 | 2011 | 212 | |
| 19 | 2008 | 26 | |
| 20 | Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation Hit paper breakdown → | 2006 | 659 |
About Holly E. Barker
Holly E. Barker is a scholar working on Immunology and Allergy, Oncology, Reproductive Medicine, Molecular Biology and Cancer Research, having authored 27 papers that have together received 3.9k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (6 papers), Microbial metabolism and enzyme function (5 papers), Angiogenesis and VEGF in Cancer (4 papers), Cancer-related Molecular Pathways (4 papers), Ovarian cancer diagnosis and treatment (3 papers), Cancer Cells and Metastasis (3 papers), Cell Adhesion Molecules Research (3 papers) and Cancer, Hypoxia, and Metabolism (2 papers). The work is most often cited by research in Oncology (1.7k citations), Cancer Research (839 citations), Immunology (638 citations), Molecular Biology (1.8k citations) and Immunology and Allergy (158 citations). Holly E. Barker has collaborated with scholars based in United Kingdom, Australia and United States. Frequent co-authors include Kevin J. Harrington, James Paget, Aadil Khan, Janine T. Erler, Thomas R. Cox, Georgina Lang, D. K. Bird, Ann‐Marie Baker, Melisa W-Y. Ho and Geoffrey J. Lindeman. Their work appears in journals such as Nature reviews. Cancer, Cancer Research, Molecular Cancer Therapeutics, Radiotherapy and Oncology and iScience.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.